Shopping Cart
- Remove All
Your shopping cart is currently empty
BAY-299 is an effecitve inhibitor of the bromodomain and PHD finger family member BRPF2 and the TATA box binding protein-associated factors TAF1 and TAF1L with IC50s of 67 nM, 8 nM, and 106 nM, respectively.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $43 | In Stock | |
| 10 mg | $70 | In Stock | |
| 25 mg | $143 | In Stock | |
| 50 mg | $253 | In Stock | |
| 100 mg | $446 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $48 | In Stock |
| Description | BAY-299 is an effecitve inhibitor of the bromodomain and PHD finger family member BRPF2 and the TATA box binding protein-associated factors TAF1 and TAF1L with IC50s of 67 nM, 8 nM, and 106 nM, respectively. |
| Targets&IC50 | TAF1L BD2:106 nM, TAF1 BD2:8 nM, BRPF2 BD:67 nM, BRPF3 BD:5550 nM, BRPF1 BD:3150 nM |
| In vitro | BAY-299 inhibits the cells proliferation of NCI-H526, CHL-1, MOLM-13, MV4-11, 769-P, Jurkat, and 5637 with GI50s of 6860, 7400, 1060, 2630, 3210, 3900, and 7980 nM, respectively. BAY-299 blocks the interaction of BRPF2 BD with H4 and H3.3 with IC50s of 575 and 825 nM, respectively[1]. |
| In vivo | The in vivo pharmacokinetic properties of BAY-299 in rats show are blood clearance is low (17% of hepatic blood flow), terminal half-life long to very long with t1/2 of 10 h, volume of distribution in steady-state high, and bioavailability high with F of 73%[1]. |
| Synonyms | BAY299, BAY 299 |
| Molecular Weight | 429.47 |
| Formula | C25H23N3O4 |
| Cas No. | 2080306-23-4 |
| Smiles | Cc1cc2n(C)c(=O)n(C)c2cc1N1C(=O)c2cccc3c(CCCO)ccc(C1=O)c23 |
| Relative Density. | 1.377 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 20 mg/mL (46.6 mM), Sonication and heating are recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.66 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.